Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

EVIO Inc. Announces the Filing of Preliminary Non-Offering Prospectus

Posted on: 02 Jul 18
EVIO Inc. Announces the Filing of Preliminary Non-Offering Prospectus

PR Newswire

BEND, Ore., July 2, 2018

BEND, Ore., July 2, 2018 /PRNewswire/ -- EVIO Inc. ("EVIO" or the "Company"), (OTCQB: EVIO), a leading provider of cannabis testing and scientific research for the regulated cannabis industry in North America, is pleased to announce it has filed and obtained a receipt for its preliminary non-offering prospectus ("Preliminary Prospectus") with the Ontario Securities Commission (the "OSC"). The filing is required for EVIO to qualify in becoming a reporting issuer in Ontario, Canada. The Preliminary Prospectus contains important information relating to EVIO and its currently issued securities and is subject to amendment as may be required by the OSC. Once the OSC has completed its review and provided its comments to the Preliminary Prospectus, the Company will proceed with filing its non-offering (final) prospectus ("Final Prospectus") with the OSC. Once the Company receives the final receipt for the Final Prospectus, the Company will apply to have its common shares listed on the Canadian Securities Exchange.

Copies of the preliminary prospectus are available on SEDAR at under EVIO's SEDAR profile.

About EVIO Inc.
EVIO Inc. is a leading provider of cannabis testing and scientific research for the regulated cannabis industry. The Company's EVIO Labs division operates coast-to-coast providing state-mandated ancillary services to ensure the safety and quality of the nation's cannabis supply.  The Company's EVIO Biosciences Division is dedicated to the scientific, medical, and psychosocial exploration of clinical cannabis, cannabinoids, and the endocannabinoid system. For more information, visit

Safe Harbor Statement
Any statements in this press release that are not statements of historical fact maybe considered to be forward-looking statements. Statements may contain certain forward-looking statements pertaining to future anticipated or projected plans, performance and developments, as well as other statements relating to future operations and results and include, but are not limited to, the filing of a non-offering (final) prospectus, the Company becoming a reporting issuer in Ontario, the obtaining of a receipt for a non-offering (final) prospectus, the completion of the listing of common shares on the Canadian Securities Exchange and the receipt of necessary approvals in connection with the transactions described herein. Words such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," or variations of these or similar words, identify forward-looking statements. These forward-looking statements by their nature are estimates of future results only and involve substantial risks and uncertainties. Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Company Contact:
Cheryl Kramp
Director of Marketing


View original content with multimedia:


PR Newswire

Last updated on: 02/07/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.